Pfizer Inc. announced the launch of a new competitive grants programme
the company is funding to support research projects investigating the
role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health
and cardiovascular disease. This competitive grants programme, which is
an extension of the Advancing Science through Pfizer Investigator
Research Exchange (ASPIRE) Cardiovascular programme, is part of Pfizer's
ongoing commitment to translate scientific discoveries into innovative
medicines for patients with cardiovascular disease. Pfizer currently is studying bococizumab, an investigational PCSK9 inhibitor, in a phase 3 clinical trial programme, known as SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events), for its potential to lower low density lipoprotein cholesterol (LDL-C) and improve cardiovascular outcomes.
No comments:
Post a Comment